Navigation Links
Mylan Announces the Conversion of its Preferred Stock into Common Stock
Date:11/15/2010

PITTSBURGH, Nov. 15, 2010 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced the completion of the conversion of 2,139,000 shares of the company's 6.50% Mandatory Convertible Preferred Stock (the "Preferred Stock") into 125,234,172 shares of the company's common stock. As previously announced, each share converted into 58.5480 shares of common stock, the minimum conversion ratio permitted by the Articles of Incorporation, reflecting strong stock performance since the preferred stock was issued. After accounting for this conversion, the total number of common shares stands at 435,218,767, based upon the number of common shares outstanding as of Nov. 12, 2010. These shares were included in the company's forecasted results under the "if converted method."

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Announces Final Conversion Rate for Mandatory Convertible Preferred Stock
2. Third Circuit Denies Mylan Motion for Interim Injunction
3. Mylan Reports Adjusted Diluted EPS of $0.43; Reaffirms 2010 Adjusted Diluted EPS Guidance of $1.55 - $1.65
4. Mylan Declares Quarterly Preferred Stock Dividend
5. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
6. Mylan Receives Approvals for Generic Versions of Hyzaar® and Cozaar®
7. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
8. Mylan Receives Approval for Fludarabine Phosphate Injection, USP
9. Mylan Launches Generic Version of Wellbutrin XL® Tablets
10. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR
11. Mylan Receives Approval for Generic Version of Prograf® Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
(Date:9/13/2017)... ATLANTA , Sept. 13, 2017   OrthoAtlanta ... to the Atlanta Football Host Committee (AFHC) for the 2018 ... Monday, Jan. 8, 2018, at Mercedes-Benz Stadium in ... part of the AFHC "I,m In" campaign, participating in many ... ...
(Date:9/12/2017)... FRANCISCO , Sept. 12, 2017  ValGenesis ... Management Solutions (VLMS), is pleased to announce the ... a member of its Board of Directors and ... ValGenesis VLMS enables life science companies to manage ... the use of paper in this process. Furthermore, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):